Analyst Price Target is $51.33
▲ +359.15% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $51.33, with a high forecast of $70.00 and a low forecast of $34.00. The average price target represents a 359.15% upside from the last price of $11.18.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Replimune Group. This Buy consensus rating has held steady for over two years.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.